5/27/2008

The European Commission has cleared Extavia, Novartis AG's treatment for early and relapsing forms of multiple sclerosis. The drug is a brand-name version of interferon beta-1b, a first-line MS therapy that has been submitted to the FDA for approval.

Related Summaries